$RLFTF. Complete article
A Swiss biotech company has obtained US approval for a Corona vehicle. Patients therefore respond well to Aviptadil, which has been developed to treat potency problems. Relief Therapeutics is now also expecting the biggest financial breakthrough.
Daniel Kestenholz
Kommentare
RELIEFTHERAPEUTICS.COM
The Swiss biotech company Relief Therapeutics hopes with Aviptadil for the big breakthrough.
1/4
The Swiss biotech company Relief Therapeutics hopes with Aviptadil for the big breakthrough.
The drug developed for potency problems therefore also shows clear advantages in the treatment of Covid patients.
2/4
The drug developed for potency problems therefore also shows clear advantages in the treatment of Covid patients.
AFP
The US Food and Drug Administration (FDA) has given Aviptadil the green light for an accelerated authorization procedure.
3/4
The US Food and Drug Administration (FDA) has given Aviptadil the green light for an accelerated authorization procedure.
RELIEFTHERAPEUTICS.COM
The Swiss Raghuram Selvaraju, Chairman of the Board of Relief Therapeutics, is convinced of the success of the Corona Medium.
4/4
The Swiss Raghuram Selvaraju, Chairman of the Board of Relief Therapeutics, is convinced of the success of the Corona Medium.
The corona pandemic is also giving new wings to the Swiss pharmaceutical industry. Lonza is producing a vaccine developed by the US group Moderna at the Welsh plant at Visp. The biotech company Relief Therapeutics, which is listed on the Swiss stock exchange, also shows great progress with a Corona device.
Relief Therapeutics, headquartered in Geneva, holds valid patents in the United States and Europe for the drug RLF-100 (Aviptadil) - a drug developed for erectile dysfunction. Aviptadil also has the potential to treat critically ill Covid-19 patients. It shows a quick recovery in case of respiratory failure.
ADVERTISING
Ads by Teads
Aviptadil is an innovative drug for inhalation in moderately and severely ill corona patients. This remedy may prevent patients from having to be connected to breathing apparatus - or they may no longer be relied on breathing machines within a few days.
Promotes blood oxygen
In early August, Aviptadil in the United States received the accelerated extended clearance procedure for respiratory failure by Covid-19. The remedy was actually developed to treat erectile dysfunction. Aviptadil is combined with another ingredient called Phentolamine to treat erectile dysfunction. When both drugs are taken together, they promote blood flow in and out of the penis, which keeps it firm. However, as tests show, Aviptadil should also treat Covid-19 patients with lung disease. X-rays thus indicate a rapid improvement in blood oxygen and that the lungs are pumping oxygen through the body again.
RLF-100 is considered to be the first drug to block the proliferation of coronavirus in human lung cells and monocytes. The hope is that by inhaling the drug in a wide range of patients with corona-causing respiratory problems, the remedy will prove to be beneficial. Clinical trials begin in September.
A first test phase will include patients in hospitals. With successful use, trials are being extended to patients at home who are only mildly or moderately ill with the virus, as Relief Therapeutics and its US partner company Neurorx announced this week.
"Hundreds of millions of dollars" revenue expected
The share value of Relief Therapeutics exploded in early August from a unit price of around 0.03 francs per share to 0.70 francs, with the price stabilizing at around 0.45 francs. The price increase followed the approval of the US Drug Administration (FDA) of Aviptadil tests.
After difficult years of operation, Board of Directors Chairman Raghuram Selvaraju (42) justifies the current stock market valuation of more than one billion francs. In an interview with the business portal "The Market", he estimates the probability of a permit at 60 to 70 percent.
The active ingredient has been used for many years for various indications. The company is confident in terms of its security. "Our active ingredient," said the Swiss, "could bring in hundreds of millions of dollars a year."
News 
Market Data 
Discover 
